GLYCOERA
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics.
GLYCOERA
Industry:
Biotechnology
Founded:
2020-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.glycoera.com
Total Employee:
11+
Status:
Active
Contact:
+41 44 733 85 75.
Email Addresses:
[email protected]
Total Funding:
45 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy SSL GoDaddy
Similar Organizations
4D Pharma
4D Pharma PLC is a world leader in the development of live biotherapeutics.
Anjarium Biosciences
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
arGEN-X
arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.
Bicycle Therapeutics
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Colossal Biosciences
Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Glaze Prosthetics
Glaze offers completely new attitude to Prosthetics.
Inthera Bioscience
Inthera Bioscience is focused on developing inhibitors of intracellular protein interactions employing a proprietary technology platform.
Lightcast Discovery
Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.
Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
NoBACZ
NoBACZ is pioneering a novel, new precision bandaging platform for the veterinary and human market.
NoPalm-Ingredients
NoPalm Ingredients produces sustainable microbial oils to replace the use of palm- and other tropical oils in food and cosmetics
Ribbon Biolabs
Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.
Simple
Simple is a game-changing AI-powered intermittent fasting platform.
Swiftscale Biologics
Swiftscale Biologics uses cell-free protein synthesis to enable the next generation of protein therapeutics.
Turbine
Turbine's platform understands the inner mechanisms of cancer enabling the discovery of novel targets & precision medicinal therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Roche Venture Fund
Roche Venture Fund investment in Series A - GlycoEra
Sofinnova Partners
Sofinnova Partners investment in Series A - GlycoEra
5AM Ventures
5AM Ventures investment in Series A - GlycoEra
LimmaTech Biologics
LimmaTech Biologics investment in Series A - GlycoEra
Key Employee Changes
Official Site Inspections
http://www.glycoera.com
- Host name: 107.223.169.192.host.secureserver.net
- IP address: 192.169.223.107
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "GlycoEra"
GlycoEra – Game-changing protein engineering
GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade …See details»
GlycoEra - Crunchbase Company Profile & Funding
GlycoEra is a CustomGlycanengineering platform that unlocks the glycan-mediated biology to develop a pipeline of novel therapeutics. ... Solutions. Products. Resources. Pricing. Resources. Log In. Organization. GlycoEra . …See details»
GlycoEra Company Profile 2024: Valuation, Funding & Investors
GlycoEra General Information Description. Operator of a biotech company intended to develop novel biologics that address high unmet medical needs in inflammatory, autoimmune, and …See details»
Org Chart GlycoEra - The Official Board
Organizational Chart of GlycoEra. GlycoEra glycoera.com. has 12 executives +41 447 338 575; Add an executive. GlycoEra News . Anything missing? We search for you. Print or download . …See details»
GlycoEra AG – Swiss Biotech
GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its proprietary platform, the CustumGlycan Platform. ... Type of organization. Private …See details»
Our Team - GlycoEra
Monique Schiersing, MSc MBA. Board Member. LinkedIn ...See details»
GlycoEra - VentureRadar
GlycoEra has developed a game-changing glycoengineering platform to build a high-value pipeline of novel biologics to address unmet medical needs. GlycoEra’s CustomGlycan …See details»
GlycoEra - Company Profile - Tracxn
Nov 5, 2024 GlycoEra ranks 45th among 201 active competitors. 12 of its competitors are funded while 49 have exited. Overall, GlycoEra and its competitors have raised over $2.52B in …See details»
GlycoEra Company Profile - Office Locations, Competitors ... - Craft
GlycoEra has 1 employees at their 1 location and $49 m in total funding,. See insights on GlycoEra including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
GlycoEra AG Company Profile | Wädenswil, ZÜRICH, Switzerland ...
Find company research, competitor information, contact details & financial data for GlycoEra AG of Wädenswil, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
GLYCOERA INC. Company Profile | Newton, MA - Dun & Bradstreet
Added by GLYCOERA INC. This information is updated and provided by GLYCOERA INC. The content available on the D&B Business Directory is provided "as-is" and "as-available" and …See details»
GlycoEra AG - top100startup.ch
News. 17.09.2024 The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100); 08.01.2024 GlycoEra has expanded Series A financing with an …See details»
GlycoEra AG raises CHF 45 Million (US$ 49 Million) Series A …
GlycoEra AG raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform. previous. GlycoEra AG Announces …See details»
GlycoEra | EU-Startups
GlycoEra is a CustomGlycanengineering platform that unlocks the glycan-mediated biology to develop a pipeline of novel therapeutics. GlycoEra AG is advancing glycoengineered …See details»
GlycoEra: CHF 45 Million financing to develop novel biologics
Nov 5, 2021 GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, …See details»
GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A …
Schlieren, SWITZERLAND – November 5, 2021 – GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European …See details»
News - GlycoEra
Nov 5, 2021 GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer . Dr. Kaundinya has been a member of the GlycoEra AG Board of Directors since the …See details»
GlycoEra AG Raises CHF 45 Million (US$ 49 Million ... - Business Wire
Nov 5, 2021 GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science inveSee details»
Programs – GlycoEra
GlycoEra Pipeline. Partner With Us. Our programs are initially focused on targeting circulating proteins that drive autoimmune diseases. However, circulating proteins drive many other …See details»
Approach – GlycoEra
GlycoEra Degraders . Bifunctional biologics for extracellular and membrane protein degradation . Our degraders bind to the disease-causing protein target and engage endocytic receptors. Our …See details»